Literature DB >> 8159750

Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits.

E Roessler1, A Grant, G Ju, M Tsudo, K Sugamura, T A Waldmann.   

Abstract

The interleukin 2 (IL-2) receptor (IL-2R) is a multisubunit receptor that includes three major IL-2 binding subunits, the IL-2R alpha, beta, and gamma chains. We have detected and analyzed cooperative interactions between the IL-2R alpha and beta chains (IL-2R alpha and IL-2R beta, respectively) in COS cells transfected with cDNAs encoding the IL-2R alpha, the IL-2R beta, or both cDNAs. We demonstrated that IL-2 F42A, an analog that fails to bind to the isolated IL-2R alpha subunit and would be predicted by the hierarchical affinity-conversion model to have impaired binding to cells expressing both chains, instead readily binds to the IL-2R alpha/beta heterodimer in COS cells. Furthermore, this binding is abolished by the antibody HIEI that separates the two IL-2R subunits. The monoclonal antibodies anti-Tac and Mik-beta 1 directed at the IL-2-binding sites on IL-2R alpha and IL-2R beta, respectively, block ligand binding to the heterodimer. This binding pattern is inconsistent with the strict hierarchical affinity-conversion model that mandates an initial binding of IL-2 to IL-2R alpha followed by binding of the IL-2/IL-2R alpha complex to IL-2R beta. Instead, our results support an alternative model of preformed complexes of IL-2R beta with other IL-2R subunits. In this alternative model, IL-2R alpha and -beta exist in part as preformed complexes in which the affinity of IL-2R beta for IL-2 is altered by the proximity of IL-2R alpha, through mechanisms that do not require the prior binding of IL-2 to IL-2R alpha.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8159750      PMCID: PMC43573          DOI: 10.1073/pnas.91.8.3344

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Evidence for p55-p75 heterodimers in the absence of IL-2 from Scatchard plot analysis.

Authors:  B Goldstein; D Jones; I G Kevrekidis; A S Perelson
Journal:  Int Immunol       Date:  1992-01       Impact factor: 4.823

Review 2.  The interleukin-2 receptor.

Authors:  T A Waldmann
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

3.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor.

Authors:  K Sauvé; M Nachman; C Spence; P Bailon; E Campbell; W H Tsien; J A Kondas; J Hakimi; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  Stepwise formation of the high-affinity complex of the interleukin 2 receptor.

Authors:  Y Saito; T Ogura; M Kamio; H Sabe; T Uchiyama; T Honjo
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

5.  The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit.

Authors:  A J Grant; E Roessler; G Ju; M Tsudo; K Sugamura; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  An associated molecule, p64, with IL-2 receptor beta chain. Its possible involvement in the formation of the functional intermediate-affinity IL-2 receptor complex.

Authors:  T Takeshita; K Ohtani; H Asao; S Kumaki; M Nakamura; K Sugamura
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

7.  c-fos gene induction by interleukin 2: identification of the critical cytoplasmic regions within the interleukin 2 receptor beta chain.

Authors:  M Hatakeyama; A Kawahara; H Mori; H Shibuya; T Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

8.  Quantitative characterization of the intrinsic ligand-binding affinity of the interleukin 2 receptor beta chain and its modulation by the alpha chain and a second affinity-modulating element.

Authors:  G E Ringheim; B D Freimark; R J Robb
Journal:  Lymphokine Cytokine Res       Date:  1991-06

9.  The IL-2 receptor alpha-chain alters the binding of IL-2 to the beta-chain.

Authors:  N Arima; M Kamio; M Okuma; G Ju; T Uchiyama
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

10.  Structure of the functional interleukin-2 receptor. Evidence for the association of human p55 and murine p75 molecules in a mouse T cell line.

Authors:  A Yamaguchi; T Ide; M Hatakeyama; T Doi; T Kono; T Uchiyama; K Kikuchi; T Taniguchi; T Uede
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

View more
  9 in total

1.  Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers.

Authors:  K Araki; K Harada; K Nakamoto; M Shiroma; T Miyakuni
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

3.  Gamma chain receptor interleukins: evidence for positive selection driving the evolution of cell-to-cell communicators in the mammalian immune system.

Authors:  Mary J O'Connell; James O McInerney
Journal:  J Mol Evol       Date:  2005-10-04       Impact factor: 2.395

4.  Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study.

Authors:  S Damjanovich; L Bene; J Matkó; A Alileche; C K Goldman; S Sharrow; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 5.  Understanding cytokine and growth factor receptor activation mechanisms.

Authors:  Mariya Atanasova; Adrian Whitty
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-10-09       Impact factor: 8.250

6.  Engineered interleukin-2 antagonists for the inhibition of regulatory T cells.

Authors:  David V Liu; Lisa M Maier; David A Hafler; K Dane Wittrup
Journal:  J Immunother       Date:  2009 Nov-Dec       Impact factor: 4.456

7.  Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division.

Authors:  L H Boise; A J Minn; C H June; T Lindsten; C B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

8.  Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Authors:  Jonathan T Sockolosky; Eleonora Trotta; Giulia Parisi; Lora Picton; Leon L Su; Alan C Le; Akanksha Chhabra; Stephanie L Silveria; Benson M George; Indigo C King; Matthew R Tiffany; Kevin Jude; Leah V Sibener; David Baker; Judith A Shizuru; Antoni Ribas; Jeffrey A Bluestone; K Christopher Garcia
Journal:  Science       Date:  2018-03-02       Impact factor: 47.728

Review 9.  Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis.

Authors:  Stanley L Cohan; Elisabeth B Lucassen; Meghan C Romba; Stefanie N Linch
Journal:  Biomedicines       Date:  2019-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.